Evidence map›Paper›PMID 39636161›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors.

Shyam Patel, Mandana Khalili, Amit G Singal, Paulo S Pinheiro, Patricia D Jones, Rebecca G Kim, Vishwajit Kode, Anna Thiemann, Wei Zhang, Ramsey Cheung and 1 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shyam PatelDepartment of Medicine, California Pacific Medical Center, San Francisco, California.ORCID 0000-0003-1181-0669
Mandana KhaliliDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-9178-9139
Amit G SingalDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-1172-3971
Paulo S PinheiroDivision of Epidemiology and Population Health Sciences, Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida.ORCID 0000-0001-8502-835X
Patricia D JonesDivision of Digestive Health and Liver Diseases, Department of Medicine, University of Miami School of Medicine, Miami, Florida.ORCID 0000-0003-4189-6731
Rebecca G KimDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.ORCID 0000-0001-7965-5760
Vishwajit KodeDepartment of Medicine, California Pacific Medical Center, San Francisco, California.ORCID 0000-0003-2501-9827
Anna ThiemannDepartment of Medicine, California Pacific Medical Center, San Francisco, California.ORCID 0000-0002-9542-9832
Wei ZhangGastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6351-6686
Ramsey CheungDivision of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.ORCID 0000-0002-0211-7013
Robert J WongDivision of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.ORCID 0000-0002-8923-2806

Funding

Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases (RCC RD-MCD)U24MD017250 · NIMHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHARLEBOIS, EDWIN DUNCAN, GANSKY, STUART A · 2021 to 2025
$22.9M
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinomaR01MD012565 · NIMHD · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT, YOPP, ADAM · 2018 to 2022
$4.3M
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease OutcomesR01CA256977 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KANWAL, FASIHA, SINGAL, AMIT · 2021 to 2025
$3.0M
Racial and Ethnic Disparities in Hepatocellular Carcinoma Surveillance Among Patients with Cirrhosis Across Five Safety Net OrganizationsR01MD017063 · NIMHD · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Robert John Wong · 2022 to 2026
$2.8M
Mentoring Multidisciplinary Patient-Oriented Research in Viral HepatitisK24AA022523 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA · 2013 to 2023
$1.9M
National Institute on Alcohol Abuse and Alcoholism (NIAAA) K24AA022523National Institute on Minority Health and Health Disparities (NIMHD) 5R01MD017063National Institute on Minority Health and Health Disparities (NIMHD) U24MD017250National Institutes of Health (NIH) R01MD012565NCI NIH HHS R01 CA256977NIAAA NIH HHS K24 AA022523NIMHD NIH HHS R01 MD012565NIMHD NIH HHS R01 MD017063NIMHD NIH HHS U24 MD017250
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the United States.

methodsUsing NCI registry data spanning 2000 to 2020, adults with HCC were evaluated to determine race/ethnicity-specific differences in tumor stage at diagnosis, delays and gaps in treatment, and survival. Adjusted regression models evaluated predictors of HCC outcomes.

resultsAmong 112,389 adults with HCC, cohort characteristics were as follows: 49.8% non-Hispanic White (NHW), 12.0% African American(AA), 20.5% Hispanic, 16.5% Asian/Pacific Islander, and 1.1% American Indian/Alaska Native. Compared with NHW patients, AA patients had lower odds of localized-stage HCC at diagnosis [adjusted odds ratio (aOR), 0.84], lower odds of HCC treatment receipt (aOR, 0.77), greater odds of treatment delays (aOR, 1.12), and significantly greater risk of death [adjusted hazards ratio (aHR), 1.10]. Compared with NHW patients from large metro areas, AA patients from large metro areas had 8% higher mortality risk (aHR, 1.08), whereas AA patients from small-medium metro areas had 17% higher mortality risk (aHR, 1.17; all P < 0.05).

conclusionsAmong a population-based cohort of US adults with HCC, significant race/ethnicity-specific disparities across the HCC care continuum were observed. Lower household income and more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients. IMPACT: Our study shows that lower income and less urban/more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients with HCC. This contextualizes the complex relationship between sociodemographic factors and HCC outcomes through an intersectional lens.

Indexed as

Carcinoma, HepatocellularEthnicityHealthcare DisparitiesLiver NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedSociodemographic FactorsUnited States

Identifiers

PMID39636161
PMCPMC11802308

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.